Publications du centre

Liste des publications

Publications du département d'ophtalmologie

Bienvenue sur la page dédiée aux publications scientifiques du département d'ophtalmologie du centre médical des Aravis. Notre équipe médicale s'investit activement dans la recherche et l'innovation afin d'améliorer constamment la prise en charge de nos patients. Nos travaux portent sur un large éventail de thématiques, notamment :

Domaines d'expertise

Les maladies de la cornée, telles que le kératocône, et les techniques chirurgicales associées (greffe de cornée, etc.).
Les pathologies rétiniennes, comme la DMLA ou le décollement de la rétine, avec une expertise particulière dans les traitements par injections intravitréennes et la chirurgie vitréo-rétinienne.
L'épidémiologie et la santé publique en ophtalmologie, en utilisant des bases de données nationales pour analyser les tendances et les facteurs de risque de différentes maladies oculaires.
L'impact des technologies numériques sur la santé oculaire, notamment l'utilisation de la télémédecine pour le dépistage de la rétinopathie diabétique.

Nous sommes fiers de partager ici nos contributions à l'avancement des connaissances en ophtalmologie. N'hésitez pas à consulter nos publications pour en savoir plus sur nos domaines d'expertise et nos recherches en cours.

Afficher tous

2022

Creuzot-Garcher, Catherine; Massin, Pascale; Srour, Mayer; Baudin, Florian; Dot, Corinne; Nghiem-Buffet, Sylvia; Girmens, Jean-Francois; Collin, Cedric; Ponthieux, Anne; Delcourt, Cecile

Epidemiology of treated diabetes ocular complications in France 2008-2018-the LANDSCAPE French nationwide study Article de journal

Dans: Pharmaceutics, vol. 14, no. 11, p. 2330, 2022.

Résumé | BibTeX | Étiquettes: France; diabetic macular edema; diabetic retinopathy; drug consumption; incidence; nationwide study; prevalence

@article{Creuzot-Garcher2022-ro,

title = {Epidemiology of treated diabetes ocular complications in France 

 2008-2018-the LANDSCAPE French nationwide study},

author = {Catherine Creuzot-Garcher and Pascale Massin and Mayer Srour and Florian Baudin and Corinne Dot and Sylvia Nghiem-Buffet and Jean-Francois Girmens and Cedric Collin and Anne Ponthieux and Cecile Delcourt},

year  = {2022},

date = {2022-10-01},

journal = {Pharmaceutics},

volume = {14},

number = {11},

pages = {2330},

publisher = {MDPI AG},

abstract = {AIM: LANDSCAPE aimed to estimate the annual incidence and 

 prevalence of treated diabetic macular edema (DME) and 

 proliferative diabetic retinopathy (PDR) between 2008 and 2018. 

 METHODS: This French nationwide observational study used data 

 from the French National Health Insurance Databases covering 

 99% of the French population. Data about healthcare consumption 

 were used to identify adults treated with anti-VEGFs or 

 dexamethasone implants (for DME) and with pan-retinal 

 photocoagulation (for PDR). All French patients newly treated 

 between 2008 and 2018 were included. Incidence and prevalence of 

 treated DME and PDR were estimated for the age-matched general 

 population and the population with diabetes in France. 

 Sociodemographic characteristics and medical history were 

 described in both populations. RESULTS: We identified 53,584 

 treated DME patients and 127,273 treated PDR patients between 

 2008 and 2018, and 11,901 DME and 11,996 PDR new incident 

 patients in 2018. The treated DME incidence in 2018 was 2.5 per 

 10,000 in the general population and 37.3 per 10,000 in the 

 population with diabetes. Prevalence in 2018 was 9.5 and 143.7 

 per 10,000 in the respective populations. Treated PDR incidence 

 in 2018 was 2.3 per 10,000 in the general population and 31.2 

 per 10,000 in the population with diabetes. Prevalence in 2018 

 was 19.9 and 270.3 per 10,000 in the respective populations. 

 Incidence and prevalence were not age-dependent. Incidence of 

 treated PDR incidence was relatively stable from 2008-2018. 

 Incidence of treated DME incidence rose from 2012-2018, probably 

 due to widening access to newly available treatments, such as 

 anti-VEGFs. CONCLUSIONS: We provide exhaustive nationwide data 

 on the incidence and prevalence of treated diabetic ocular 

 complications in France over a 10-year period.},

keywords = {France; diabetic macular edema; diabetic retinopathy; drug   consumption; incidence; nationwide study; prevalence},

pubstate = {published},

tppubtype = {article}

}

Fermer

Explorer

Recherche

Creuzot-Garcher, Catherine; Massin, Pascale; Srour, Mayer; Baudin, Florian; Dot, Corinne; Nghiem-Buffet, Sylvia; Girmens, Jean-Francois; Collin, Cedric; Ponthieux, Anne; Delcourt, Cecile

Epidemiology of treated diabetes ocular complications in France 2008-2018-the LANDSCAPE French nationwide study Article de journal

Dans: Pharmaceutics, vol. 14, no. 11, p. 2330, 2022.

Résumé | BibTeX

@article{Creuzot-Garcher2022-ro,

title = {Epidemiology of treated diabetes ocular complications in France 

 2008-2018-the LANDSCAPE French nationwide study},

author = {Catherine Creuzot-Garcher and Pascale Massin and Mayer Srour and Florian Baudin and Corinne Dot and Sylvia Nghiem-Buffet and Jean-Francois Girmens and Cedric Collin and Anne Ponthieux and Cecile Delcourt},

year  = {2022},

date = {2022-10-01},

journal = {Pharmaceutics},

volume = {14},

number = {11},

pages = {2330},

publisher = {MDPI AG},

abstract = {AIM: LANDSCAPE aimed to estimate the annual incidence and 

 prevalence of treated diabetic macular edema (DME) and 

 proliferative diabetic retinopathy (PDR) between 2008 and 2018. 

 METHODS: This French nationwide observational study used data 

 from the French National Health Insurance Databases covering 

 99% of the French population. Data about healthcare consumption 

 were used to identify adults treated with anti-VEGFs or 

 dexamethasone implants (for DME) and with pan-retinal 

 photocoagulation (for PDR). All French patients newly treated 

 between 2008 and 2018 were included. Incidence and prevalence of 

 treated DME and PDR were estimated for the age-matched general 

 population and the population with diabetes in France. 

 Sociodemographic characteristics and medical history were 

 described in both populations. RESULTS: We identified 53,584 

 treated DME patients and 127,273 treated PDR patients between 

 2008 and 2018, and 11,901 DME and 11,996 PDR new incident 

 patients in 2018. The treated DME incidence in 2018 was 2.5 per 

 10,000 in the general population and 37.3 per 10,000 in the 

 population with diabetes. Prevalence in 2018 was 9.5 and 143.7 

 per 10,000 in the respective populations. Treated PDR incidence 

 in 2018 was 2.3 per 10,000 in the general population and 31.2 

 per 10,000 in the population with diabetes. Prevalence in 2018 

 was 19.9 and 270.3 per 10,000 in the respective populations. 

 Incidence and prevalence were not age-dependent. Incidence of 

 treated PDR incidence was relatively stable from 2008-2018. 

 Incidence of treated DME incidence rose from 2012-2018, probably 

 due to widening access to newly available treatments, such as 

 anti-VEGFs. CONCLUSIONS: We provide exhaustive nationwide data 

 on the incidence and prevalence of treated diabetic ocular 

 complications in France over a 10-year period.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

Fermer